Could a probiotic protect Insulin-Making cells in newly diagnosed type 1 diabetes?
NCT ID NCT04335656
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a probiotic called Lactiplantibacillus plantarum (Lp299v) can reduce inflammation and help preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes. The study includes 60 participants aged 3 to 45 who were diagnosed within the last 100 days. Half will take the probiotic daily for 6 months, and the other half will take a placebo, with researchers measuring changes in inflammation and insulin production.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Lactiplantibacillus plantarum (Lp299v) probiotic
- What this could lead to
- If it works, this could point toward a way to help preserve the body's own insulin production in people newly diagnosed with type 1 diabetes.
- What could go wrong
- This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The probiotic may not reduce inflammation or slow disease progression as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2021
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
3 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. ≤ 100 days from T1D diagnosis based on ADA criteria 2. \> 21 days from T1D diagnosis or metabolically stable per study physician assessment 3. Males and females 3-45 years of age, inclusive, at time of screening visit 4. Peak MMTT stimulated C-peptide ≥ 0.2 nmol/L 5. Positive for at least 1 diabetes autoantibody (excluding mIAA in those who have received ≥ 2 weeks of exogenous insulin therapy) either through clinically obtained labs at time of diagnosis or as obtained at the screening visit 6. Females of child-bearing potential (defined as any female who has reached menarche (first menses), excluding those who have had a hysterectomy or are post-menopausal and must be willing to use effective birth control (which may include abstinence)) from screening visit until final study visit 7. Willing and able to give informed consent or have parent or legal guardian provide informed consent if the subject is \< 18 years of age Exclusion Criteria: 1. Probiotic supplement use within the past month 2. Antibiotic use within the past month 3. Concurrent or recent (within the past 30 days of screening) use of non-insulin therapies aimed to control hyperglycemia 4. Females who are pregnant or lactating 5. Chronic inflammatory or autoimmune disease with exception of stable thyroid disease 6. Uncontrolled celiac disease (i.e., consuming gluten) or actively being evaluated for possible celiac disease (i.e., clinically obtained tissue transglutaminase IgA titers above reference range, being referred to gastroenterology for possible endoscopy, etc.) 7. Use of glucocorticoids or other immunosuppressive agents within 30 days of screening MMTT 8. Use of medications known to influence glucose tolerance 9. Dairy allergy 10. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a glucose sensor and family coaching tame type 1 diabetes in toddlers?
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Can a math model tune insulin pumps better than standard care?
- Can a group program stop eating disorders in type 1 diabetes?
- Can a smartphone app help heal diabetic foot wounds?
- Can a handoff plan help teens with chronic illness take charge of their care?